Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Pfizer, inc. save search
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.34%
H: 3.99%
C: 3.15%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 0.91%
H: 5.05%
C: 4.9%
arv-471 fda breast cancer treatment designation
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.78%
H: 0.3%
C: -0.84%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.4%
H: 0.07%
C: -0.92%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.21%
H: 0.72%
C: -0.11%
authorization cancer treatment application
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.56%
H: 1.25%
C: -0.33%
keytruda drug japan bladder cancer treatment application advanced
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -6.38%
H: 0.88%
C: 0.88%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.09%
H: 0.17%
C: -0.3%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.58%
H: 1.01%
C: -0.58%
keytruda bladder cancer treatment application advanced
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Published: 2023-12-17 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.7%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.79%
H: 0.35%
C: -0.26%
UVV | $51.46 1.9% 0.0% 190K
|
Consumer Non-Durables
|
| O: 0.0%
H: 0.05%
C: -1.86%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.09%
H: 1.41%
C: 0.52%
children treatment ema
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.38%
H: 1.79%
C: 1.79%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.5%
H: 0.3%
C: 0.0%
xtandi fda approved cancer treatment
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 06:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.32%
H: 0.23%
C: -3.06%
nefecon nephropathy drug approval treatment application
Global Vulvovaginal Candidiasis Treatment Market Research Report 2023-2028 - Demand for Cost-effective Vulvovaginal Candidiasis Treatment Soars with Growing Geriatric Population
Published: 2023-10-04 (Crawled : 23:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.59%
H: 0.29%
C: 0.22%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.42%
H: 0.99%
C: 0.06%
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.45%
H: 4.04%
C: 0.45%
CDTX | $0.6855 -5.06% -5.32% 350K
|
Health Technology
|
| O: 0.39%
H: 10.33%
C: 3.9%
report treatment candidiasis research global growing market
Global Bronchial Spasms Treatment Market Set to Reach $505.07 Million by 2031 with a CAGR of 4.1%
Published: 2023-09-20 (Crawled : 22:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: -0.63%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.45%
H: 0.36%
C: -1.85%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -1.57%
reach treatment global set market
Optic Nerves Disorder Treatment Market Rises: North America Takes the Helm
Published: 2023-09-14 (Crawled : 00:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.84%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.47%
H: 0.41%
C: -0.26%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.28%
H: 1.0%
C: 0.76%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.78%
H: 1.76%
C: 1.07%
america treatment market
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.03%
H: 1.04%
C: -0.37%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.18%
H: 1.2%
C: -0.38%
xtandi cancer treatment
Global Obesity Treatment Market Poised to Reach $26.44 Billion by 2028, Fueled by Rising Prevalence and Innovative Interventions
Published: 2023-08-25 (Crawled : 02:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.06%
H: 1.52%
C: 0.66%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.34%
H: 1.29%
C: 0.93%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.98%
H: 1.19%
C: 0.82%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.11%
H: 0.44%
C: -0.22%
obesity reach treatment global market
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Published: 2023-06-28 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.22%
H: 0.11%
C: -0.58%
OPK | $1.23 0.0% 2.7M
|
Health Technology
|
| O: 24.1%
H: 0.97%
C: -16.5%
fda treatment growth hormone
Global Axial Spondyloarthritis Treatment Market to 2027: Increase in the Number of Approved Biosimilars Fuels the Sector
Published: 2023-06-16 (Crawled : 02:00) - prnewswire.com
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 1.21%
H: 0.0%
C: -0.2%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.28%
H: 1.25%
C: 0.5%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.46%
H: 0.31%
C: -0.15%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.41%
H: 0.26%
C: -1.77%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
approved treatment global market
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2023-06-01 (Crawled : 17:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.26%
H: 0.24%
C: -0.26%
hope treatment infections
Stomach Cancer Treatment Market Report 2023: Growing Demand for Painless Low-Cost Treatment and Favorable Reimbursement Scenarios Bolsters Sector
Published: 2023-04-14 (Crawled : 02:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.08%
H: 0.49%
C: -0.76%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.24%
H: 0.55%
C: 0.13%
report favorable cancer treatment growing market
Optic Nerve Disorder Treatment Market to Reach USD 5.3 Billion, Globally, by 2031 at 4.5% CAGR: Allied Market Research
Published: 2023-02-27 (Crawled : 07:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.74%
H: 0.7%
C: -1.59%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.64%
H: 0.01%
C: -0.72%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.36%
H: 0.97%
C: 0.67%
treatment research market
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
Published: 2023-02-23 (Crawled : 09:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 1.09%
C: 0.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.55%
C: 0.01%
treatment biktarvy positive
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
Published: 2023-02-14 (Crawled : 15:00) - biospace.com/
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.74%
H: 2.37%
C: 1.92%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.23%
H: 0.25%
C: -0.84%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.33%
H: 0.06%
C: -0.14%
treatment hiv biktarvy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.